Inside Ownership Ordinary Shares %IPD Issued Net Value at $0.08
Christine Emmanuel-Donnelly 389,809 0% $31,185
Parmjot Bains 21,673 0% $1,734
Janelle Delaney 3,930,122 0% $314,410
Andrew Grant 400,000 0% $32,000
Total 4,741,604 0.23% $379,328
Current Market Cap ~$161.8m
Management Buying
Christine Emmanuel-Donnelly
· 14 May 2024
Indirect 100,000 shares average price $0.08 ($8000)
Andrew Grant
· 6 May 2024
Direct 100,000 shares average price $0.0805 ($8050)
Janelle Delaney
· 6-8 May 2024
Indirect 634,177 shares average price $0.079 ($50099.983)
Christine Emmanuel-Donnelly, BSc -Non-Executive Chair
Christine Emmanuel-Donnelly was appointed to the Board in September 2023. Christine is an experienced ASX listed company Director and Intellectual Property specialist. She is currently a Non-Executive Director for PolyNovo and Medical Developments International and non-ASX listed Pikcha Holdings Pty Ltd (trading as Seminal). Previous executive experience includes commercialisation and intellectual property roles at CSIRO,and RMIT. CSIRO is the premier Australian science agency covering all scientific disciplines, where she led and managed the Intellectual property portfolio and led the IP team, the commercialisation team and the equity portfolio team across all Business Units. Christine previously practised as a patent and trade marks attorney in leading AU and UK firms and Unilever (UK).
Parmjot Bains, MD - Managing Director & Interim CEO
Dr. Parmjot Bains was appointed Managing Director and Chief Executive Officer of ImpediMed in January 2024. She is a high caliber healthcare executive with diverse experience including strategy, sales and marketing, commercial execution, and change management across the United States, Asia, Middle East, and Australia. Most recently, Dr. Bains was Pfizer’s Gulf Cluster Country Manager, responsible for setting commercial strategy, aligning team capabilities, driving private and public reimbursement, accelerating sales and marketing activities and key account management. Dr. Bains managed a large team across six countries and six therapeutic areas including breast cancer, and successfully delivered significant growth against clear metrics and targets in various markets. Her other former roles include joint CEO and COO at Neuren Pharmaceuticals, CEO of Perseis Therapeutics, a Manager at McKinsey and Company. Dr Bains trained and practiced as a Medical Doctor in New Zealand and Australia.
Janelle Delaney, MBA - Non-Executive Director
Janelle Delaney was appointed to the Board in September 2023. Janelle has over three decades of extensive IT experience covering all facets from sales through software development, project/program delivery and business management. As a Partner at IBM Consulting, she is responsible for the quality of project delivery across IBM Consulting Asia Pacific’s portfolio of several thousand projects and across all solutions (including digital transformation, AI, package implementations, application management services).
Andrew Grant, BEE, MBA - Non-Executive Director
Andrew Grant was appointed to the Board in September 2023. Andrew is a highly qualified and globally experienced healthcare management professional. His experience covers Australia, USA, Europe and Asia as a medical device and hospital sector executive. He spent five years with ResMed in roles encompassing VP Global Product Marketing and VP Corporate Development and three years with Luye Medical International where he facilitated a technology transfer of Cleveland Clinic’s cardiac and oncology service lines to Luye’s International Hospital start-up project in China. Prior experience included engineering design and development of implantable pacemakers and defibrillators, and management consulting with McKinsey & Co.
McGregor Grant, BEc, cA, GAICD, FGIA, FCIS
McGregor joined the Board in September 2023 and was appointed as Chair at that time. He was appointed as Executive Chair and interim CFO in November 2023. Mr. Grant has over 26 years’ experience in the medical device and healthcare industries in Australia and the United States. Most recently, Mr. Grant was the CFO and Company Secretary of Nanosonics Limited. In that role he gained extensive commercial experience leading Nanosonics from start up through growth and business maturation to become a successful global business with operations in North America, Europe and Asia Pacific. Mr. Grant has extensive international experience gained with Invacare as the Asia Pacific Finance Director, and Abbott Laboratories in a number of senior finance roles located in Australia and the United States. Previously Mr. Grant worked for Coopers & Lybrand (now PwC) in Australia and Europe.
